<DOC>
	<DOC>NCT01996839</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel</brief_summary>
	<brief_title>Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</brief_title>
	<detailed_description>The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel, 0.38% (BID and TID) for the treatment of postoperative inflammation and pain following cataract surgery.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Visit 1 (Screening Visit) Be willing and able to comply with all treatment and followup/study procedures. Be a candidate for routine, uncomplicated cataract surgery Visit 3 (Postoperative Day 1) Have undergone routine, uncomplicated cataract surgery (phaco emulsification with posterior chamber IOL implantation, not combined with any other surgery) in the study eye. Have â‰¥ Grade 2 anterior chamber (AC) cells (615 cells) in the study eye. Have a severe/serious ocular condition or history/presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the result(s) of the study. Have known hypersensitivity or contraindication to the study drug(s) or their components.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>